These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 17697087)

  • 1. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.
    Liechty CA; Solberg P; Were W; Ekwaru JP; Ransom RL; Weidle PJ; Downing R; Coutinho A; Mermin J
    Trop Med Int Health; 2007 Aug; 12(8):929-35. PubMed ID: 17697087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptococcal antigenemia in anti-retroviral naïve AIDS patients: prevalence and its association with CD4 cell count.
    Osazuwa OF; Dirisu O; Okuonghae E
    Acta Med Iran; 2012; 50(5):344-7. PubMed ID: 22837089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptococcal disease in patients with or without human immunodeficiency virus: clinical presentation and monitoring of serum cryptococcal antigen titers.
    Lin TY; Yeh KM; Lin JC; Wang NC; Peng MY; Chang FY
    J Microbiol Immunol Infect; 2009 Jun; 42(3):220-6. PubMed ID: 19812855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
    Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
    BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Disseminated cryptococcosis in patients with AIDS. Clinical, microbiological, and immunological analysis of 51 patients].
    Metta HA; Corti ME; Negroni R; Helou S; Arechavala A; Soto I; Villafañe MF; Muzzio E; Castello T; Esquivel P; Trione N
    Rev Argent Microbiol; 2002; 34(3):117-23. PubMed ID: 12415893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in Uganda.
    Andama AO; den Boon S; Meya D; Cattamanchi A; Worodria W; Davis JL; Walter ND; Yoo SD; Kalema N; Haller B; Huang L;
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):189-94. PubMed ID: 23542636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.
    Pac L; Horwitz MM; Namutebi AM; Auerbach BJ; Semeere A; Namulema T; Schwarz M; Bbosa R; Muruta A; Meya DB; Manabe YC
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):e69-76. PubMed ID: 25761234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy.
    Lortholary O; Poizat G; Zeller V; Neuville S; Boibieux A; Alvarez M; Dellamonica P; Botterel F; Dromer F; Chêne G
    AIDS; 2006 Nov; 20(17):2183-91. PubMed ID: 17086058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts.
    Pongsai P; Atamasirikul K; Sungkanuparph S
    J Infect; 2010 Jun; 60(6):474-7. PubMed ID: 20347868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No association of cryptococcal antigenemia with poor outcomes among antiretroviral therapy-experienced HIV-infected patients in Addis Ababa, Ethiopia.
    Smitson CC; Tenna A; Tsegaye M; Alemu AS; Fekade D; Aseffa A; Blumberg HM; Kempker RR
    PLoS One; 2014; 9(1):e85698. PubMed ID: 24465651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
    Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
    BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.
    Rajasingham R; Meya DB; Greene GS; Jordan A; Nakawuka M; Chiller TM; Boulware DR; Larson BA
    PLoS One; 2019; 14(1):e0210105. PubMed ID: 30629619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
    Moh R; Danel C; Messou E; Ouassa T; Gabillard D; Anzian A; Abo Y; Salamon R; Bissagnene E; Seyler C; Eholié S; Anglaret X
    AIDS; 2007 Nov; 21(18):2483-91. PubMed ID: 18025885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.
    Vidal JE; Toniolo C; Paulino A; Colombo A; Dos Anjos Martins M; da Silva Meira C; Pereira-Chioccola VL; Figueiredo-Mello C; Barros T; Duarte J; Fonseca F; Alves Cunha M; Mendes C; Ribero T; Dos Santos Lazera M; Rajasingham R; Boulware DR
    Trop Med Int Health; 2016 Dec; 21(12):1539-1544. PubMed ID: 27699970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis.
    Chen J; Zhang R; Shen Y; Liu L; Qi T; Wang Z; Mehraj V; Routy JP; Lu H
    HIV Med; 2019 Jan; 20(1):69-73. PubMed ID: 30311440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study.
    Mussini C; Pezzotti P; Miró JM; Martinez E; de Quiros JC; Cinque P; Borghi V; Bedini A; Domingo P; Cahn P; Bossi P; de Luca A; d'Arminio Monforte A; Nelson M; Nwokolo N; Helou S; Negroni R; Jacchetti G; Antinori S; Lazzarin A; Cossarizza A; Esposito R; Antinori A; Aberg JA;
    Clin Infect Dis; 2004 Feb; 38(4):565-71. PubMed ID: 14765351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda.
    Moore D; Liechty C; Ekwaru P; Were W; Mwima G; Solberg P; Rutherford G; Mermin J
    AIDS; 2007 Mar; 21(6):713-9. PubMed ID: 17413692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis.
    Tan DB; Yong YK; Tan HY; Kamarulzaman A; Tan LH; Lim A; James I; French M; Price P
    HIV Med; 2008 May; 9(5):307-16. PubMed ID: 18400078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
    Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
    Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
    Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.